摘要 |
The invention relates to an in vitro method for the prognosis or prediction of the response in patients with rheumatoid arthritis treated with agents that recognize the CD20 membrane receptor in B lymphocytes. The method according to the invention consists in determining if at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, HLA-DQA1, NLK,TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770,ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orf145 and SNTA1 is present in a blood sample from said patients and quantifying the transcriptional expression level thereof (mRNA) prior to initiating the treatment; and comparing said expression level with respect to expression values previously obtained from patients shown to be responders to the treatment and from patients shown to be non-responders to the treatment. |